BioCentury article: CD38 Hat Trick

This article is also available in pdf format. Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates effector T cells. The CD38 space initially gained prominence based on the speedy development and commercial success of … Read More

UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer

London and Stevenage, UK Tusk Therapeutics, an immuno-oncology company, today announces that its collaborators, Dr. Sergio Quezada and Professor Karl Peggs of the Cancer Immunology group at University College London (UCL), published work in Immunity, a peer-reviewed medical journal, on targeting CD25 with an optimised antibody for the treatment of cancer. The paper entitled, Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T … Read More